PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) Market Outlook

Thelansis’s “PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) Overview

Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a hereditary cardiac disorder characterized by impaired function of the right ventricle (RV) and the occurrence of ventricular arrhythmias, which can ultimately lead to sudden cardiac death. The condition is characterized by the replacement of cardiomyocytes with fibrofatty tissue. ARVD/C is typically inherited in an autosomal dominant manner, but it exhibits incomplete penetrance, and the expression of the disease varies significantly with age. In rare cases, autosomal recessive inheritance can occur with or without cutaneous involvement. The progressive fibrotic replacement process leads to electrical instability, increasing the risk of syncope and sudden cardiac death, or causing alterations in cardiac function, resembling dilated cardiomyopathy, which may result in right- or bi-ventricular heart failure. The diagnosis of ARVD/C is challenging and relies on applying the 2010 Task Force criteria, which consider family history, distinctive electrocardiographic findings, arrhythmic events, and structural and histological abnormalities. Mutations in the PKP2 gene are responsible for 9-43% of ARVC cases and are considered the most common genetic cause of the condition. However, it should be noted that a single pathogenic variant in PKP2 may not be sufficient to cause the full manifestation of the disease. The PKP2 gene encodes a protein that belongs to the Armadillo (ARM) repeat family. Plakophilin proteins, including Plakophilin-2, contain multiple ARM repeats and are localized in cell desmosomes and nuclei. They play a crucial role in linking cadherins to intermediate filaments in the cytoskeleton. Plakophilin-2 is essential for the assembly of junctional proteins and serves as a vital morphogenic factor and architectural component in the heart. ARVC often exhibits familial clustering, with a family history of the condition present in 30-50% of cases.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034